Atomoxetine

Summary

Atomoxetine (CHEMBL641) is an approved small-molecule adrenergic uptake inhibitor (ATC N06BA09) targeting SLC6A2, SLC6A3, and SLC6A4; indicated across 22 conditions including attention deficit-hyperactivity disorder and autism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06BA09
• Targets: 3 (SLC6A2, SLC6A3, SLC6A4)
• Indications: 22 conditions
• Clinical trials: 138
• Chemistry: 255.35 Da · C17H21NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL641
Name	Atomoxetine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	54841
ChEBI	CHEBI:127342
ATC	N06BA09
Molecular formula	C17H21NO
Molecular weight	255.35
InChIKey	VHGCDTVCOLNTBX-QGZVFWFLSA-N

SMILES: CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2

IUPAC name: (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine

ChEBI definition: A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.

Pharmacological roles (ChEBI): adrenergic uptake inhibitor, antidepressant.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Atomoxetina, Atomoxetine, Atomoxetine component of ad-109, Atomoxetine component of ad-313, Atomoxetine component of ad109, Atomoxetine component of ad313, atomoxetine, Tomoxetine, SID11114266, ATOMOXETINE

Parent form; salt/anhydrous children: CHEMBL1702

Patent coverage: 3,515 distinct patent families (13,098 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,008 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC6A2	NET	Inhibition	8.69	0.4%	P23975
SLC6A3	DAT	Inhibition	5.97	0.2%	Q01959
SLC6A4	SERT	Inhibition	8.05	0.7%	P31645

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: Inositol monophosphatase 1, 5-hydroxytryptamine receptor 2B, Alpha-2B adrenergic receptor, Thyrotropin receptor, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Sodium-dependent serotonin transporter, Histamine H1 receptor, Mu-type opioid receptor, D(3) dopamine receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Histamine H3 receptor, Cytochrome P450 2D6, Sodium-dependent serotonin transporter, Glutamate receptor ionotropic, NMDA 1, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 52 potent at pChembl ≥ 5 of 70 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	8.69	Kd	2.03	nM	CHEMBL_ACT_154563
SLC6A2	8.52	IC50	3	nM	CHEMBL_ACT_2483370
SLC6A2	8.52	IC50	3	nM	CHEMBL_ACT_2522733
SLC6A2	8.52	IC50	3	nM	CHEMBL_ACT_2587127
SLC6A2	8.52	IC50	3	nM	CHEMBL_ACT_3185270
SLC6A2	8.51	IC50	3.1	nM	CHEMBL_ACT_2699893
SLC6A2	8.3	IC50	5	nM	CHEMBL_ACT_2242033
SLC6A2	8.3	IC50	5	nM	CHEMBL_ACT_2243435
SLC6A2	8.3	IC50	5	nM	CHEMBL_ACT_2447142
SLC6A2	8.3	IC50	5	nM	CHEMBL_ACT_2591094
SLC6A2	8.29	IC50	5.1	nM	CHEMBL_ACT_2100181
SLC6A2	8.29	IC50	5.1	nM	CHEMBL_ACT_2169358
SLC6A2	8.29	IC50	5.1	nM	CHEMBL_ACT_2397248
SLC6A2	8.06	AC50	8.8	nM	CHEMBL_ACT_25144547
SLC6A4	8.05	Kd	8.9	nM	CHEMBL_ACT_154562
SLC6A2	8.05	IC50	8.9	nM	CHEMBL_ACT_29265422
SLC6A4	7.75	AC50	18	nM	CHEMBL_ACT_25149884
P31652	7.37	Ki	43	nM	CHEMBL_ACT_154566
SLC6A4	7.32	IC50	48	nM	CHEMBL_ACT_2483388
SLC6A4	7.32	IC50	48	nM	CHEMBL_ACT_2522760
SLC6A4	7.32	IC50	48	nM	CHEMBL_ACT_2587142
P31652	7.11	Ki	77	nM	CHEMBL_ACT_717099
SLC6A4	6.75	IC50	180	nM	CHEMBL_ACT_2242074
SLC6A4	6.75	IC50	180	nM	CHEMBL_ACT_2243436
SLC6A4	6.75	IC50	180	nM	CHEMBL_ACT_2447143
SLC6A4	6.75	IC50	180	nM	CHEMBL_ACT_2591102
SLC6A4	6.72	IC50	190	nM	CHEMBL_ACT_2100221
SLC6A4	6.72	IC50	190	nM	CHEMBL_ACT_2169404
SLC6A4	6.72	IC50	190	nM	CHEMBL_ACT_2397345
P23977	6.15	Ki	708	nM	CHEMBL_ACT_1230149
SLC6A3	5.97	Kd	1080	nM	CHEMBL_ACT_154564
P23977	5.85	Ki	1400	nM	CHEMBL_ACT_154568
P23977	5.84	Ki	1451	nM	CHEMBL_ACT_717098
P31652	5.82	Ki	1500	nM	CHEMBL_ACT_2265481
OPRK1	5.75	AC50	1800	nM	CHEMBL_ACT_25129011
CYP2D6	5.7	IC50	2000	nM	CHEMBL_ACT_2243438
P23977	5.7	IC50	2000	nM	CHEMBL_ACT_2265483
CYP2D6	5.7	IC50	2000	nM	CHEMBL_ACT_2591156
KCNH2	5.68	IC50	2100	nM	CHEMBL_ACT_2397213
SLC6A3	5.52	IC50	3000	nM	CHEMBL_ACT_2242030
SLC6A3	5.52	IC50	3000	nM	CHEMBL_ACT_2243437
SLC6A3	5.52	IC50	3000	nM	CHEMBL_ACT_2447144
SLC6A3	5.52	IC50	3000	nM	CHEMBL_ACT_2591129
SLC6A3	5.51	IC50	3100	nM	CHEMBL_ACT_2100262
SLC6A3	5.51	IC50	3100	nM	CHEMBL_ACT_2169450
SLC6A3	5.51	IC50	3100	nM	CHEMBL_ACT_2397374
KCNH2	5.47	AC50	3400	nM	CHEMBL_ACT_25117161
SLC6A3	5.36	AC50	4400	nM	CHEMBL_ACT_25123490
HTR2A	5.2	AC50	6380	nM	CHEMBL_ACT_25224747
CYP2D6	5.2	Potency	6310	nM	CHEMBL_ACT_5002477
CYP2D6	5.2	AC50	6310	nM	CHEMBL_ACT_5987413
P97697	5	Potency	10000	nM	CHEMBL_ACT_4412502

Target pathways

Aggregated over 3 target gene(s): SLC6A2, SLC6A3, SLC6A4.

Top Reactome pathways

15 total, by targets touching each:

Pathway	Targets	Genes
SLC-mediated transport of neurotransmitters	3	SLC6A2, SLC6A3, SLC6A4
Neurotransmitter clearance	2	SLC6A3, SLC6A4
Transmission across Chemical Synapses	2	SLC6A3, SLC6A4
Neuronal System	2	SLC6A3, SLC6A4
Disease	2	SLC6A2, SLC6A3
Transport of small molecules	2	SLC6A2, SLC6A3
R-HSA-425366	2	SLC6A2, SLC6A3
SLC-mediated transmembrane transport	2	SLC6A2, SLC6A3
SLC transporter disorders	2	SLC6A2, SLC6A3
Disorders of transmembrane transporters	2	SLC6A2, SLC6A3
Dopamine clearance from the synaptic cleft	1	SLC6A3
Serotonin clearance from the synaptic cleft	1	SLC6A4
Defective neurotransmitter clearance by SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)	1	SLC6A3
Defective SLC6A2 causes orthostatic intolerance (OI)	1	SLC6A2
Defective transport of neurotransmitters by SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)	1	SLC6A3

Dominant GO biological processes

GO term	Targets
neurotransmitter transport	3
amino acid transport	3
response to xenobiotic stimulus	3
obsolete monoamine transport	3
sodium ion transmembrane transport	3
transmembrane transport	3
dopamine uptake involved in synaptic transmission	2
norepinephrine uptake	2
neurotransmitter reuptake	2
chemical synaptic transmission	1
obsolete norepinephrine transport	1
response to pain	1
neuron cellular homeostasis	1
catecholamine uptake	1
chloride transmembrane transport	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
attention deficit-hyperactivity disorder	4	MONDO:0007743	EFO:0003888

16 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
autism	3	MONDO:0005260	EFO:0003758
neoplasm	3	MONDO:0005070	MONDO:0004992
obstructive sleep apnea syndrome	2	MONDO:0007147	EFO:0003918
orthostatic hypotension	2	MONDO:0005469	EFO:0005252
opiate dependence	2	MONDO:0005530	EFO:0005611
sleep apnea syndrome	2	MONDO:0005296	EFO:0003877
cannabis dependence	2	MONDO:0005689	EFO:0007191
Tourette syndrome	2	MONDO:0007661	EFO:0004895
substance-related disorder	2	MONDO:0002494	MONDO:0002491
social phobia	2	MONDO:0001247	EFO:1001917
alcohol abuse	2	MONDO:0002046	MONDO:0007079
drug dependence	2	MONDO:0005303	EFO:0003890
cocaine dependence	1	MONDO:0005186	EFO:0002610
nicotine dependence	1	MONDO:0008575	EFO:0003768
methamphetamine dependence	1	MONDO:0005419	EFO:0004701
postural orthostatic tachycardia syndrome	1	MONDO:0011479	EFO:1000645

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 138.

Phase distribution

Phase	Trials
PHASE4	40
PHASE2	34
Not specified	22
PHASE3	18
PHASE1	10
PHASE1/PHASE2	9
EARLY_PHASE1	3
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03781765	PHASE4	RECRUITING	Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
NCT06573970	PHASE4	NOT_YET_RECRUITING	Atomoxetine and Executive Function in PTSD
NCT00181740	PHASE4	COMPLETED	Concerta Treatment in Adults With ADHD NOS
NCT00181948	PHASE4	COMPLETED	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00183391	PHASE4	COMPLETED	Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
NCT00190957	PHASE4	COMPLETED	Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00191035	PHASE4	COMPLETED	Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191048	PHASE4	COMPLETED	Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191633	PHASE4	COMPLETED	Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00222794	PHASE4	COMPLETED	A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
NCT00252278	PHASE4	UNKNOWN	Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
NCT00254462	PHASE4	COMPLETED	Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
NCT00299234	PHASE4	TERMINATED	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
NCT00304161	PHASE4	COMPLETED	Effectiveness of Antidepressant Treatment for Depression in People With Parkinson’s Disease
NCT00327834	PHASE4	COMPLETED	Atomoxetine in the Treatment of Binge Eating Disorder
NCT00380692	PHASE4	COMPLETED	Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
NCT00406354	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00471354	PHASE4	COMPLETED	A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
NCT00488163	PHASE4	COMPLETED	Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
NCT00546910	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00566371	PHASE4	COMPLETED	The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents
NCT00585910	PHASE4	COMPLETED	Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
NCT00607919	PHASE4	COMPLETED	Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
NCT00628394	PHASE4	COMPLETED	Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
NCT00687609	PHASE4	TERMINATED	Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
NCT00716274	PHASE4	COMPLETED	Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
NCT00760747	PHASE4	COMPLETED	Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT00918567	PHASE4	COMPLETED	Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
NCT00938743	PHASE4	COMPLETED	Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine
NCT01065259	PHASE4	COMPLETED	Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children
NCT01127646	PHASE4	TERMINATED	A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
NCT01133847	PHASE4	COMPLETED	Interventions for Children With Attention and Reading Disorders
NCT01207622	PHASE4	WITHDRAWN	Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD
NCT01339286	PHASE4	UNKNOWN	Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)
NCT02287038	PHASE4	COMPLETED	Atomoxetine in Veterans With Comorbid ADHD/PTSD
NCT02352051	PHASE4	COMPLETED	Effects of Atx and Oros-mph on Executive Functions
NCT02623114	PHASE4	UNKNOWN	Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers
NCT03350659	PHASE4	COMPLETED	Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
NCT03661788	PHASE4	COMPLETED	Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological ‘Resting State’ and ‘Inhibiton Task’ Study in Patients With ADHD
NCT04216186	PHASE3	RECRUITING	Role of Coenzyme Q in ADHD in Children
NCT06566820	PHASE3	ENROLLING_BY_INVITATION	Continuation Protocol for Obstructive Sleep Apnea (OSA)
NCT07316296	PHASE3	RECRUITING	Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson’s Disease: a Multi-centre and Multi-modal Approach
NCT00190684	PHASE3	COMPLETED	Long-Term, Open Label Atomoxetine Study
NCT00191295	PHASE2/PHASE3	COMPLETED	Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT00191516	PHASE3	COMPLETED	An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
NCT00191542	PHASE3	COMPLETED	Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
NCT00191737	PHASE3	COMPLETED	An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
NCT00191880	PHASE3	COMPLETED	Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
NCT00192023	PHASE3	COMPLETED	An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
NCT00255138	PHASE3	WITHDRAWN	Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
NCT00260533	PHASE2/PHASE3	COMPLETED	Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
NCT00320528	PHASE3	COMPLETED	Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00386581	PHASE3	COMPLETED	Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
NCT00418262	PHASE3	COMPLETED	Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
NCT00447278	PHASE3	COMPLETED	A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00962104	PHASE3	COMPLETED	Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
NCT00969618	PHASE3	COMPLETED	A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
NCT01330693	PHASE3	UNKNOWN	Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
NCT00262470	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Treatment of Orthostatic Intolerance
NCT05293600	PHASE1/PHASE2	RECRUITING	Rescue Pharmacotherapy for OSA
NCT05933603	PHASE2	ACTIVE_NOT_RECRUITING	Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
NCT06542887	PHASE2	NOT_YET_RECRUITING	Black Seed Oil in ADHD
NCT06899178	PHASE2	NOT_YET_RECRUITING	Atomoxetine in Melanocortin Obesity Syndrome
NCT00029614	PHASE2	COMPLETED	Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD
NCT00089869	PHASE1/PHASE2	COMPLETED	A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
NCT00142961	PHASE2	COMPLETED	Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
NCT00167297	PHASE2	COMPLETED	Atomoxetine for the Treatment of Cannabis Dependence
NCT00174226	PHASE2	COMPLETED	Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
NCT00218543	PHASE2	COMPLETED	Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00360269	PHASE2	COMPLETED	Atomoxetine Treatment for ADHD and Marijuana Dependence
NCT00368849	PHASE2	COMPLETED	Atomoxetine and Huntington’s Disease
NCT00420498	PHASE2	COMPLETED	Effects of Atomoxetine on Cognitive Function in Schizophrenia
NCT00429091	PHASE2	COMPLETED	A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00528697	PHASE2	COMPLETED	A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00530335	PHASE2	COMPLETED	Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT00548327	PHASE2	TERMINATED	The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
NCT00562055	PHASE2	WITHDRAWN	Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
NCT00607568	PHASE1/PHASE2	COMPLETED	Atomoxetine Effects in Humans
NCT00611936	PHASE1/PHASE2	COMPLETED	Effects of Atomoxetine Treatment in Humans
NCT00617201	PHASE2	COMPLETED	Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
NCT00636818	PHASE2	COMPLETED	Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00880217	PHASE2	COMPLETED	A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01522404	PHASE2	COMPLETED	Effects of Atomoxetine in Mild Cognitive Impairment
NCT01557569	PHASE1/PHASE2	COMPLETED	Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
NCT01738191	PHASE2	COMPLETED	Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog)
NCT01863251	PHASE2	COMPLETED	Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
NCT02046551	PHASE1/PHASE2	WITHDRAWN	Atomoxetine’s Effects On Nicotine Response And Stress Response In Smokers
NCT02500732	PHASE2	COMPLETED	Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
NCT02784535	PHASE2	COMPLETED	Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
NCT02788357	PHASE2	COMPLETED	Post-stroke Neural Plasticity With Atomoxetine
NCT03091400	PHASE2	COMPLETED	Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
NCT03324581	PHASE2	COMPLETED	The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
NCT03919955	PHASE2	COMPLETED	A Novel Pharmacological Therapy for Obstructive Sleep Apnea
NCT04115878	PHASE2	COMPLETED	Medications for Obstructive Sleep Apnea In Children With Down Syndrome
NCT04354103	PHASE2	TERMINATED	Atomoxetine in Patients With Tourette’s Syndrome
NCT04445688	PHASE2	COMPLETED	Crossover Trial of AD036 in Obstructive Sleep Apnea
NCT04565288	PHASE2	COMPLETED	Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine
NCT04580394	PHASE2	COMPLETED	Crossover Trial of AD109 in Obstructive Sleep Apnea

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (2) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for atomoxetine and CYP2D6	DPWG	CYP2D6	yes	yes
Annotation of CPIC Guideline for atomoxetine and CYP2D6	CPIC	CYP2D6	yes	yes

PharmGKB also curates 6 clinical and 40 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

664 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
Idelalisib	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
Olodaterol	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
Tadalafil	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
UMECLIDINIUM	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
VORAPAXAR	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
AMIODARONE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ASENAPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BENFLUOREX	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BENZTROPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BENZYDAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BEPRIDIL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BOSUTINIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BROMHEXINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BROMPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
BUPROPION	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CABERGOLINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CALCITRIOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CARVEDILOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CELECOXIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CETIRIZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CINNARIZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CITALOPRAM	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CLEMASTINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CLOMIPHENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
COBIMETINIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
COCAINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DANAZOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DEQUALINIUM	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DESIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DESLORATADINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DESOGESTREL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DESVENLAFAXINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DEXBROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DEXTROAMPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DOBUTAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DOMPERIDONE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DOTHIEPIN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DOXAZOSIN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DRONEDARONE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
DULOXETINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
EBASTINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ECONAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
EPALRESTAT	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ERDAFITINIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FEDRATINIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FENOLDOPAM	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FENOTEROL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FIPEXIDE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FLUOXETINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
FLUVOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
GUANABENZ	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
HALOPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
HALOPROGIN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
HEXAFLUORENIUM	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
HEXETIDINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
IDARUBICIN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ILOPERIDONE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
IMIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
INDACATEROL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
ISOCONAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
KETOCONAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
LABETALOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
LEVOMILNACIPRAN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3, SLC6A4